Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.
This study describes the natural course of vincristine-induced peripheral neuropathy in patients with lymphoma (n = 114) receiving vincristine in two different dose intensities. Neuropathic changes were observed in both dose intensity groups, but the higher dose intensity group reported significantly more symptoms during therapy, whereas neurologic signs were significantly more prominent after a cumulative dose of 12 mg vincristine. Furthermore, off-therapy worsening of symptoms (24%) and signs (30%) occurred unexpectedly.
Verstappen
C C P
CC
Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands.
Koeppen
S
S
Heimans
J J
JJ
Huijgens
P C
PC
Scheulen
M E
ME
Strumberg
D
D
Kiburg
B
B
Postma
T J
TJ
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D018908:Muscle Weakness / Q000139:chemically induced / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000294:innervation / Q000503:physiopathology; D009437:Neuralgia / Q000139:chemically induced / Q000503:physiopathology; D010292:Paresthesia / Q000139:chemically induced / Q000503:physiopathology; D010525:Peripheral Nerves / Q000187:drug effects* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D011446:Prospective Studies; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects*; D028761:Withholding Treatment
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine